durvalumab,sorafenib,tremelimumab
pfizer,astrazeneca
['hcc', 'himalaya', 'astrazeneca']
at #wcgic2023, we shared a 4-year overall survival update from our himalaya phase iii trial for patients with unresectable hepatocellular carcinoma (#hcc), the most common form of #livercancer. read about the results and what they mean for patients here: 
The official Twitter feed for AstraZeneca US. For more info visit http://t.co/5VlUaVGyiC.